Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Current Liabilities: 2012-2025

Historic Total Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $48.6 million.

  • Enanta Pharmaceuticals' Total Current Liabilities fell 15.61% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 15.61%. This contributed to the annual value of $48.6 million for FY2025, which is 15.61% down from last year.
  • Enanta Pharmaceuticals' Total Current Liabilities amounted to $48.6 million in FY2025, which was down 15.61% from $57.5 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Total Current Liabilities ranged from a high of $62.8 million in FY2023 and a low of $29.8 million during FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $57.5 million (2024), whereas its average is $56.3 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Total Current Liabilities dropped by 17.54% in 2022 and then spiked by 110.50% in 2023.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Total Current Liabilities stood at $36.2 million in 2021, then declined by 17.54% to $29.8 million in 2022, then spiked by 110.50% to $62.8 million in 2023, then declined by 8.36% to $57.5 million in 2024, then declined by 15.61% to $48.6 million in 2025.